# GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)

> **NCT00509457** · NA · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** GV 1001 Telomerase peptide

## Key facts

- **NCT ID:** NCT00509457
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2009-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2011-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509457, "GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00509457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*